Skip to content

MONTPHARMA

Active Private limited companyfounded 2023active for 2 yearsAlsembergse Steenweg 314, 1190 ForestKBO/BCE: BE 1003.738.776

Lifetime

2 annual accounts with figures on one time axis
peak of €88,530 in 2024
€55,087▼ 37.8%
peak of €68,590 in 2024
€41,561▼ 39.4%
peak of €111,460 in 2025
€111,460▲ 57.6%
€24,027▲ 84.1%
Board2 names since 2023
1 director
Documentsfilings and deeds
05-03-2026148 days before the deadline
2025micro format
Gross margin from €88,530 to €55,087Result from €68,590 to €41,561Dividend €833Equity from €70,731 to €111,460Debts from €13,051 to €24,027Cash from €69,564 to €120,584

Key points

from the 2025 annual accounts

Equity

€111,460 ▲ 57.6%
70,7312024+41,561Profit-833Dividend111,4602025

MONTPHARMA paid out €833 in dividends. That is 2% of the 2025 profit.

Turnover

≈ €270,000 estimated

The micro format states no turnover.

Position in the sector

82.3%

Higher solvency than 89% of companies in retail trade. The sector median is 33.2%, over 25,388 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 39,329 companies had the same profile as MONTPHARMA has now. Each dot stands for 99 companies, two years later.

95.7%
were still trading
2.4%
stopped another way
1.8%
went bankrupt
  • Micro
  • 2 to 5 years old
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more
Test of the method

The method was tested on the 497,965 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 39,329 companies, not a prediction for MONTPHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director
Director
  • 100 sharesdeed of 27-12-2023
Board & ownership

Recent changes

Registered office moved from Saintes to Forest The registered office moved from rue de Saintes 27 à 1430 Saintes to Chaussée d'Alsemberg 314 à 1190 Forest · General meeting of 15-06-2026 · Gazette deed
appointed as director General meeting of 21-04-2026 · Gazette deed
Registered in the Peppol Directory Reachable for e-invoices through 0208:1003738776
First establishment Rue de Saintes 27, Rebecq
All 8 events

Comparable companies

same main activity, similar in size and age
Company
MONTPHARMA Forest €135,487 €55,087 82.3% -
O.Sabur Genk €129,423 €57,943 57.1% -
NOVAPLEX Modave €119,122 €52,898 77.1% -
Farma Jana Lo-Reninge €118,424 €57,937 80.1% -
API PHARMA Liège €116,460 €52,678 59.7% -
KARBON PLUS Diksmuide €127,790 €52,214 80.4% -
ELIAM Hasselt €122,187 €65,184 84.3% -

These companies have the same main activity as MONTPHARMA: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €116,000 and €129,000, founded between 2023 and 2024.

Official details

Source: KBO
Status
Active since 21-12-2023Normal situation
Activity
Retail sale of pharmaceutical productsNACE 47730and 2 others
Establishment unit
2.353.342.1401430 Rebecq, since 27-12-2023
Financial year end
31 December
Peppol
Reachable since 12-02-2026
Company details

Annual accounts 2025

€135,487▲ 61.7%
Filing
Filed on 05-03-2026, 148 days before the end of the filing period
Financials

Insights on MONTPHARMA

MONTPHARMA has been active since 2023 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €111,460 and a net result of €41,561.

Its solvency ranks better than 89% of 25,388 sector peers (NACE 47) in financial year 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about MONTPHARMA

What is the company number of MONTPHARMA?
The company number of MONTPHARMA is 1003.738.776. The VAT number is the same number with BE in front: BE 1003.738.776.
Where is MONTPHARMA based?
The registered office is at Alsembergse Steenweg 314, 1190 Forest.Company details
What does MONTPHARMA do?
According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of MONTPHARMA?
MONTPHARMA is a private limited company (BV).
When was MONTPHARMA founded?
MONTPHARMA was founded on 21-12-2023.
Is MONTPHARMA still active?
Yes, MONTPHARMA is an active enterprise in the KBO register.
What is the turnover of MONTPHARMA?
The turnover in financial year 2025 is about €270,000. This figure is estimated from the gross margin of €55,087 and 54 comparable companies (NACE 477). It probably lies between €130,000 and €380,000.Financials
Is MONTPHARMA profitable?
In financial year 2025, MONTPHARMA made a profit of €41,561.
Where can I find the annual accounts of MONTPHARMA?
MONTPHARMA filed 2 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of MONTPHARMA due?
MONTPHARMA must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.